Table 1.
Characteristics of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral reports in U.S. military personnel to VAERS, October 2011 through July 2018.
| Report characteristics | Military No. (%) |
Military observational study5 No. (%) |
Total No. (%) |
|---|---|---|---|
| Total Reports | 71 | 29 | 100 |
| Serious1,2 | 22 (31) | 17 (58.6) | 39 (39) |
| Male | 50 (70.4) | 22 (75.9) | 72 (72) |
| Median onset interval (range) days | 0 (0–366) | 5 (0–367) | 1 (0–367) |
| Adenovirus vaccine given alone3 | 4 (5.6) | 1 (3.4) | 5 (5) |
| Median age (range) years | 19 (17–32) | 19.5 (18–27) | 19 (17–32) |
| Age groups years4 | |||
| 17–19 | 37 (52.1) | 2 (6.9) | 39 (39) |
| 20–29 | 32 (45.1) | 2 (6.9) | 34 (34) |
| ≥30 | 2 (2.8) | 0 | 2 (2) |
| Unknown age | 0 | 25 (86.2) | 25 (25) |
1
Includes death, life-threatening illness, hospitalization or prolongation of existing hospitalization, or permanent disability.
2
One of the serious reports was a death.
3
Other most commonly given concomitant vaccines included: Meningococcal conj. in 78 (78%), seasonal influenza in 74 (74%), Tdap in 68 (68%), Hepatitis A/B combined in 26 (26%). Hepatitis B in 20 (20%).
4
Age not reported in 25 (25%) reports.
5
Sentinel Surveillance Plan-FDA-mandated post-marketing study.